Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest balloon catheter Stories

2014-01-29 16:29:00

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/gfr88r/global_peripheral) has announced the addition of the "Global Peripheral Vascular Devices - Market Growth Analysis" [http://www.researchandmarkets.com/research/gfr88r/global_peripheral ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The broad health care' division has been witnessing a rapid growth and...

2013-10-29 08:31:06

New Scientific Method Delivers Diagnostic & Therapeutic Agents Directly to Target Tissues SAUSALITO, Calif., Oct. 29, 2013 /PRNewswire/ -- Sanovas Inc., (www.sanovas.com) a life science technology company focused on developing and commercializing next generation micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office issued patent # 8,540,667 for the company's Multi-Balloon Catheter for Extravasated Drug...

2013-07-18 08:29:30

More Mature Markets in Western Europe Will See Marginal Declines, According to Millennium Research Group TORONTO, July 18, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, markets for interventional cardiology (IC) devices have reached maturation in Belgium, Sweden, Switzerland and the Netherlands, while Eastern European markets will continue to see growth. Procedure volume growth will be slight in...

2013-05-03 12:25:24

HUDSON, N.H., May 3, 2013 /PRNewswire/ -- Atrium Medical Corporation, a business unit of MAQUET Cardiovascular, today announced the 1-year results of the INFUSE-AMI (Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction) trial. Dr. Gregg Stone, the principle investigator, presented the exciting findings at the 62(nd) Annual American College of Cardiology Conference in San Francisco, CA. INFUSE-AMI's primary endpoint was reduction in infarct size (also...

2012-11-19 08:27:54

SAUSALITO, Calif., Nov. 19, 2012 /PRNewswire/ -- Sanovas, Inc., a life science technology company focused on developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's nested balloon catheter for localized drug delivery, a component of Sanovas' Vas Zeppelin(TM) Smart Catheter technology portfolio. The...

2012-10-22 07:30:40

LAGUNA HILLS, Calif., Oct. 22, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it would present the latest REDUCE-HTN renal denervation clinical study data at this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting to be held Oct. 22-26 at the Miami Beach Convention Center in Miami. On October 25, Dr. Eric Wyffels of the...

2012-10-02 06:26:20

LAGUNA HILLS, Calif., Oct. 2, 2012 /PRNewswire/ -- Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012. Vessix was chosen as one of the Fierce 15 based, in part, on the innovation, creativity and promise of the Vessix V2 Renal Denervation...

2012-09-27 02:27:23

NATICK, Mass., Sept. 27, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration clearance for the Emerge(TM) Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Dilatation Catheter and has begun marketing the device in the United States. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional deliverability for physicians to address challenging lesions in coronary...

2012-07-16 02:23:46

PLEASANTON, Calif., July 16 /PRNewswire/ -- TriReme Medical, Inc. (TMI) announced today that it has received FDA clearance for an expanded matrix of sizes for its unique Glider(TM) PTCA balloon catheter. Glider(TM) is now approved for the treatment of lesions in the coronary vasculature in balloon diameters from 1.5 - 3.5mm and in lengths from 4mm to 20mm. "Glider(TM) provides interventional cardiologists with an entirely new degree of control during the treatment of complex side...

2012-05-23 02:26:07

PLEASANTON, Calif., May 23, 2012 /PRNewswire/ -- TriReme Medical, Inc. (TMI) today announced approval by the U.S. Food and Drug Administration (FDA) of the Glider(TM) PTCA Catheter, indicated for treating the stenotic portion of coronary arteries or bypass grafts to improve myocardial perfusion. Glider(TM) is the world's only torqueable PTCA balloon catheter. Combined with its state of the art tip technology, Glider(TM) is designed to perform, even in the most challenging conditions. It is...


Latest balloon catheter Reference Libraries

Interventional Radiology
2013-03-04 16:18:42

Interventional radiology (IR) is a special sub-operation under general radiology. It is used to find, diagnose and treat a disease in almost every body system. The process of interventional radiology is very noninvasive to help with the recovery and outcome of the procedure. It utilizes x-rays, CT, ultrasound, MRI, and other modes of imaging in order to direct tools in the body as well as a variety of catheters, narrow tubes, so that incisions can be minimalized. How it is Performed...

More Articles (1 articles) »